Trypanosoma cruzi LPS Specific Neutra™ Antibody Products

Are you struggling with prolonged drug development timelines or challenges in targeting Trypanosoma cruzi lipopolysaccharide (LPS)? Creative Biolabs' T. cruzi LPS specific Neutra™ antibody products leverage advanced protein engineering and high-throughput epitope mapping to deliver robust, affinity-optimized tools for rapid therapeutic discovery and diagnostic innovation.

Introduction to T. cruzi LPS

T. cruzi, the protozoan parasite responsible for Chagas disease, expresses a unique LPS critical for its survival and virulence. T. cruzi LPS is distinct from bacterial endotoxins, featuring a complex glycosylphosphatidylinositol (GPI)-anchored structure enriched with glycoinositolphospholipids. This molecule plays a central role in immune evasion and host cell invasion, making it a high-value target for therapeutic intervention.

• Basic Information

T. cruzi LPS is a surface-exposed glycoconjugate expressed throughout the parasite's life cycle, particularly during the infectious trypomastigote stage. Its conservation across T. cruzi strains and involvement in host-pathogen interactions underscore its relevance in both basic research and translational applications.

Fig.1 Process of invasion of T. cruzi into the host cell, involving LPS molecules.¹

• Structure

The LPS comprises a lipid anchor linked to a glycan core modified with variable side chains, including galactose, sialic acid, and β-glucose residues. This heterogeneity enables immune system manipulation by mimicking host glycans. Cryo-EM studies reveal dynamic spatial arrangements that facilitate receptor binding and membrane fusion, while X-ray crystallography has mapped key epitopes for antibody recognition.

• Related Signaling Pathways

T. cruzi LPS interacts with Toll-like receptor 4 (TLR4) and CD14 on macrophages, triggering pro-inflammatory cytokine release (e.g., TNF-α, IL-6) and oxidative bursts. Paradoxically, it also suppresses host NF-κB and MAPK pathways to dampen antimicrobial responses, enabling persistent infection. These dual mechanisms highlight LPS as a master regulator of immune evasion.

• Related Diseases

Chagas disease, transmitted by triatomine bugs or contaminated blood, affects 6–7 million people globally. Chronic infection leads to cardiomyopathy, digestive megasyndromes, and brain dysfunction. Current therapies exhibit limited efficacy in late-stage disease, emphasizing the need for novel antibody-based strategies targeting LPS-mediated pathogenesis.

Applications of Anti-T. cruzi LPS Neutralizing Antibodies

• Diagnostic Assay Development

Anti-T. cruzi LPS antibodies enable rapid, high-sensitivity detection of circulating parasites in blood samples. Lateral flow assays and ELISA kits incorporating these antibodies improve early diagnosis in endemic regions, reducing reliance on invasive tissue biopsies.

• Therapeutic Candidate Evaluation

Neutralizing antibodies block LPS binding to host receptors, preventing cellular invasion and parasite replication. In preclinical models, passive immunization with these antibodies reduces parasitemia and mitigates cardiac tissue damage, supporting their use as standalone therapies or adjuncts to small-molecule drugs.

• Vaccine Efficacy Assessment

Quantifying anti-LPS antibody titers in vaccinated subjects provides surrogate markers of immune protection. Our antibodies facilitate standardized serological testing to benchmark vaccine candidates during clinical trials.

• Host-Pathogen Interaction Research

These tools are indispensable for elucidating LPS-driven immune evasion mechanisms. Applications include flow cytometry to study macrophage-parasite interactions and immunohistochemistry to map LPS distribution in infected tissues.

Our Anti- T. cruzi LPS Antibody Products

Creative Biolabs' T. cruzi LPS specific antibodies are engineered for high specificity and neutralizing capacity. Key features include:

- Epitope Precision: Targets conserved glycoepitopes critical for parasite adhesion and immune evasion.

- Functional Validation: Demonstrated neutralization of trypomastigote infectivity in in vitro and in vivo models.

- Cross-Reactivity Control: Rigorous screening ensures minimal off-target binding to host glycans.

Applications span diagnostic development, therapeutic candidate screening, and mechanistic studies of LPS-mediated immune modulation.

Creative Biolabs provides T. cruzi LPS specific Neutra™ antibody products, empowering researchers to overcome barriers in Chagas disease research and drug development. With unmatched specificity and proven neutralization efficacy, our antibodies are vital for diagnostic innovation, therapeutic discovery, and mechanistic studies.

Contact us today to discuss your project and receive custom solutions tailored to your needs.

REFERENCE

1. Watanabe Costa, Renata, Jose F. da Silveira, and Diana Bahia. "Interactions between Trypanosoma cruzi secreted proteins and host cell signaling pathways." Frontiers in microbiology 7 (2016): 388. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fmicb.2016.00388